KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBT Margin (2018 - 2025)

Vir Biotechnology (VIR) has disclosed EBT Margin for 8 consecutive years, with 67.21% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 77872.0% to 67.21% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 638.56% through Dec 2025, up 11380.0% year-over-year, with the annual reading at 638.56% for FY2025, 6639.0% up from the prior year.
  • EBT Margin hit 67.21% in Q4 2025 for Vir Biotechnology, up from 67905.42% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 106.9% in Q3 2021 to a low of 67905.42% in Q3 2025.
  • Historically, EBT Margin has averaged 5856.14% across 5 years, with a median of 647.3% in 2022.
  • Biggest five-year swings in EBT Margin: skyrocketed 861301bps in 2022 and later plummeted -5893315bps in 2025.
  • Year by year, EBT Margin stood at 67.17% in 2021, then plummeted by -557bps to 306.9% in 2022, then plummeted by -134bps to 719.35% in 2023, then fell by -18bps to 845.93% in 2024, then soared by 92bps to 67.21% in 2025.
  • Business Quant data shows EBT Margin for VIR at 67.21% in Q4 2025, 67905.42% in Q3 2025, and 9125.86% in Q2 2025.